Wells Fargo raised the firm’s price target on Ascendis Pharma to $260 from $196 and keeps an Overweight rating on the shares. The firm thinks TransCon palopegteriparatide might be closer to a EUR 3B drug vs. the Street’s EUR 2B estimate by 2030, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ASND:
- Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024
- Ascendis Pharma A/S Is Worried About This – Should You Be Worried Too?
- Ascendis Pharma price target raised to $225 from $207 at Wedbush
- Ascendis Pharma price target raised to $182 from $146 at Citi
- Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results
